Top Banner
LOSS OF HETEROZYGOSITY Tumorigenesis , Alfred G. Knudson in the early 1970s. Hereditary retinoblastoma and sporadic tumors had similar molecular mutations involving the retinoblastoma gene. Knudson’s hypothesis Tumor suppressor gene (TSG).
14

LOSS OF HETEROZYGOSITY

Feb 24, 2016

Download

Documents

etana

LOSS OF HETEROZYGOSITY. Tumorigenesis , Alfred G. Knudson in the early 1970s. Hereditary retinoblastoma and sporadic tumors had similar molecular mutations involving the retinoblastoma gene. Knudson’s hypothesis Tumor suppressor gene (TSG). - PowerPoint PPT Presentation
Welcome message from author
This document is posted to help you gain knowledge. Please leave a comment to let me know what you think about it! Share it to your friends and learn new things together.
Transcript
Page 1: LOSS OF HETEROZYGOSITY

LOSS OF HETEROZYGOSITYTumorigenesis , Alfred G. Knudson in the early 1970s. Hereditary retinoblastoma and sporadic tumors had similar molecular mutations involving the retinoblastoma gene.

Knudson’s hypothesisTumor suppressor gene (TSG).

Page 2: LOSS OF HETEROZYGOSITY

In the sporadic, nonhereditary situation, normal cells have two functional copies of a wild-type (nonmutated) TSG, one inherited from each parent.

Two Hit ModelOne copy of the TSG develops an

inactivating mutation and is termed the first genetic hit.

can also be inherited in cancer syndromes that make patients susceptible to tumors.

REMEMBER1st hit alone not enough for tumorigenesis WHY????What you think TSGsRecessive orDominant(Think before you speak)

Page 3: LOSS OF HETEROZYGOSITY

The second genetic hit alters the second copy of the TSG; this hit commonly occurs from larger deletion mutations. It is uncommon for cells to have two large deletion mutations (biallelic deletion).

The cells that harbor two mutated copies of the TSG have a loss of function of the TSG activity, and this contributes to carcinogenesis.

Page 4: LOSS OF HETEROZYGOSITY

Knudson’s hypothesis AND Familial colon cancer progression.

In this classic model, germline mutations in the familial adenomatous polyposis gene (APC, on chromosome 5q21) are inherited as the first hit, and somatic mutations (usually deletions) in the second copy of the APC gene represent the second hit.

The colonic adenoma–to–carcinoma pathway is probably one of the best-studied examples of tumorigenesis using a tumor suppressor pathway. DysplasiaNeoplasia

In fact, TSGs have been implicated as being a part of tumorigenesis in nearly every type of sporadic tumor.

Page 5: LOSS OF HETEROZYGOSITY

Many studies have used the deletion of a TSG as a surrogate marker for inactivation of the TSG. Deletions of TSGs can be assessed in several assays. One of the most common isthe loss of heterozygosity (LOH).

INFORMATIVE vs NON INFORMATIVE GENOTYPE

When an individual has inherited two copies of a polymorphism that are different from each other (have different numbers of repeats on each copy), they are said to have an “informative genotype” at that locus.

If an individual is homozygous for the

polymorphism, the locus is noninformative and the PCR products will be identical whether both are present or one allele is deleted.

Page 6: LOSS OF HETEROZYGOSITY
Page 7: LOSS OF HETEROZYGOSITY

A SINGLE NUCLEOTIDE POLYMORPHISM WITH TWO DIFFERENT ALLELE POSSIBILITIES.

Page 8: LOSS OF HETEROZYGOSITY

A TETRANUCLEOTIDE UNIT THAT IS HETEROZYGOUS OR INFORMATIVE

Page 9: LOSS OF HETEROZYGOSITY

APPEARANCE OF MONO, DI AND TETRANUCLEOTIDE STRs

Page 10: LOSS OF HETEROZYGOSITY

TYPICAL APPEARANCE OF A SINGLE PCR PRODUCT (P) ANALYZED ON CAPILLARY ELECTROPHORESIS

Page 11: LOSS OF HETEROZYGOSITY

LOH ANALYSIS OF NORMAL CELLS (A) AND TUMOR CELLS (B)

Page 12: LOSS OF HETEROZYGOSITY

Electropherograms from a normal sample from a patient with an oligodendroglioma. Two different areas of tumor were microdissected, and polymerase chain reaction was performed for a marker on 1p. The two tumor samples show loss of the larger allele (*). The ratio of the peak heights is measured in relative fl uorescent units and given in the box next to each peak. The ratio of the allele heights in the tumor is compared to that in the normal sample to assess for loss of heterozygosity.

Page 13: LOSS OF HETEROZYGOSITY
Page 14: LOSS OF HETEROZYGOSITY

ASSIGNMENT(a. NOMENCLATURE FOR DESCRIBING SEQUENCE CHANGESSee www.dmd.nl/mutnomen.html and Den Dunnen and Antonarakis (2001) for full details.

(b. VARIOUS WAYS TO REDUCE OR ABOLISH THE PRODUCTION OF A FUNCTIONING GENE PRODUCT